Loading cancer entity…
Loading cancer entity…
Clinical trials
972 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00489203 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 140 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT01169636 | Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 6, 2021 |
| clinicaltrials |
| NCT02227433 | Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease.(FIL_BVHD01) | completed | Phase 2 | 20 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT00670592 | Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | completed | Phase 1 / Phase 2 | 111 | Novartis PharmaceuticalsINDUSTRY | 11 | Dec 17, 2020 | clinicaltrials |
| NCT00510315 | Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant | completed | — | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 7, 2020 | clinicaltrials |
| NCT03114683 | Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma(ORIENT-1) | completed | Phase 2 | 96 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Dec 7, 2020 | clinicaltrials |
| NCT02181478 | Intra-Osseous Co-Transplant of UCB and hMSC | completed | Early Phase 1 | 6 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT01584141 | Study of Lymphoma in Asia | completed | — | 13,433 | National Cancer Institute (NCI)NIH | 3 | Nov 27, 2020 | clinicaltrials |
| NCT00691210 | Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies(SAHA) | completed | Phase 1 | 40 | Columbia UniversityOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT01572519 | A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 1 | 21 | Janssen Research & Development, LLCINDUSTRY | 2 | Nov 20, 2020 | clinicaltrials |
| NCT02181218 | Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas | completed | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT00515554 | HD18 for Advanced Stages in Hodgkins Lymphoma | completed | Phase 3 | 1,500 | University of CologneOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT02321592 | GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma(GHSG-AFM13) | completed | Phase 2 | 23 | University of CologneOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT01943682 | Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma | completed | Phase 1 | 27 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Nov 9, 2020 | clinicaltrials |
| NCT01258998 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2020 | clinicaltrials |
| NCT04005703 | Whole-body MRI in Pediatric Hodgkin's Lymphoma | completed | — | 75 | UMC UtrechtOTHER | 4 | Nov 3, 2020 | clinicaltrials |
| NCT01075321 | Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 58 | Mayo ClinicOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT00478959 | Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma | completed | Phase 2 | 30 | University Health Network, TorontoOTHER | 0 | Sep 18, 2020 | clinicaltrials |
| NCT04396119 | Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study | completed | — | 30 | The Christie NHS Foundation TrustOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT03242902 | To Decrease Fatigue With Light Therapy(SPARKLE) | completed | Phase 3 | 166 | The Netherlands Cancer InstituteOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT02505269 | Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma | completed | Phase 2 | 34 | Massachusetts General HospitalOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT01921387 | Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 4, 2020 | clinicaltrials |
| NCT04464590 | Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT(LYMPHOTEP1) | completed | — | 100 | University Hospital, BrestOTHER | 0 | Jul 9, 2020 | clinicaltrials |
| NCT01217229 | Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 2 | 20 | Daiichi SankyoINDUSTRY | 1 | Jun 30, 2020 | clinicaltrials |
| NCT01854567 | P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies | completed | Phase 3 | 49 | Mesoblast, Ltd.INDUSTRY | 1 | Jun 26, 2020 | clinicaltrials |
| NCT00062868 | LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma(ALCI) | completed | Phase 1 | 74 | Baylor College of MedicineOTHER | 1 | Jun 9, 2020 | clinicaltrials |
| NCT03343652 | A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma(NB001) | completed | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT02003625 | Meloxicam vs Placebo for Mobilization | completed | Phase 2 | 31 | Massachusetts General HospitalOTHER | 1 | May 18, 2020 | clinicaltrials |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT01611298 | Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR(TAR) | completed | N/A | 7 | Robert KranceOTHER | 1 | Apr 21, 2020 | clinicaltrials |
| NCT00967369 | Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment. | completed | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 20, 2020 | clinicaltrials |
| NCT00002561 | Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease | completed | Phase 3 | 405 | NCIC Clinical Trials GroupNETWORK | 3 | Apr 14, 2020 | clinicaltrials |
| NCT00566696 | Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies | completed | Phase 2 | 73 | St. Jude Children's Research HospitalOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT00082888 | Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma | completed | Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2020 | clinicaltrials |
| NCT01356680 | HD17 for Intermediate Stage Hodgkin Lymphoma | completed | Phase 3 | 1,100 | University of CologneOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT02164500 | JAK-inhibition in Recurrent Classical Hodgkin Lymphoma(JeRiCHO) | completed | Phase 2 | 12 | University of CologneOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT04298619 | Follow Up of High Risk Hodgkin Lymphoma in First Complete Remission(HOLYFU) | completed | — | 123 | Federico II UniversityOTHER | 0 | Mar 6, 2020 | clinicaltrials |
| NCT00654732 | Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma | completed | Phase 2 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2020 | clinicaltrials |
| NCT01447056 | Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases(MALTED) | completed | Phase 1 | 37 | Baylor College of MedicineOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT00068718 | Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant | completed | Phase 1 / Phase 2 | 35 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 31, 2020 | clinicaltrials |
| NCT00096161 | Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant | completed | Phase 2 | 36 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 31, 2020 | clinicaltrials |
| NCT00789776 | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer | completed | Phase 1 / Phase 2 | 41 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT00005803 | Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma | completed | Phase 1 / Phase 2 | 76 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 29, 2020 | clinicaltrials |
| NCT00040846 | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies | completed | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 29, 2020 | clinicaltrials |
| NCT03343665 | Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma(Nivo40) | completed | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00014235 | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | completed | N/A | 160 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Feb 3, 2021source: clinicaltrials